Advanced Medical Solutions Group reports on CE approval to market new product
PHMB has been shown to be effective against several bacteria including, amongst others, Staphylococcus Aureus including the methicillin resistant type, (MRSA) and Escherichia Coli (E-Coli). This antimicrobial foam wound dressing may be used throughout the healing process on moderate to heavily exuding chronic and acute wounds that are infected or are at risk of infection and may be used on pressure ulcers, leg and foot ulcers, diabetic ulcers and surgical wounds.
AMS expects to launch this product through its OEM partners in 2015, as well as including it in its ActivHeal® range of woundcare dressings for the NHS.
Chris Meredith, Chief Executive Officer of AMS, commented: "We are pleased to receive CE approval for this AMS product which strengthens our position in the antimicrobial foam market and look forward to launching it in EU markets and into the NHS later this year."
Комментарии